口服奥利司司特:在中重度银屑病中的疗效与安全性及改良释放片的开发
2a期前瞻性随机双盲安慰剂对照试验显示,口服奥利司司特速释制剂30 mg治疗16周可显著改善中重度银屑病患者的平均银屑病面积严重度指数评分。1期单中心试验表明,改良释放与速释制剂药代动力学特性相当,且改良释放组胃肠道相关不良事件少于速释组(16.7% vs 33.3%)。未来奥利司司特的开发将基于改良释放制剂。
要点
- 奥利司司特速释制剂30 mg治疗16周可显著改善中重度银屑病患者的平均PASI评分。
- 改良释放与速释制剂药代动力学特性相当,改良释放组胃肠道不良事件更少(16.7% vs 33.3%)。
- 未来奥利司司特的开发将基于改良释放制剂。
核心结论
- 在中重度银屑病患者中,奥利司司特速释制剂在16周时显示出优于安慰剂的疗效。
- 在健康参与者中,奥利司司特改良释放制剂与速释制剂药代动力学特性相似,且胃肠道疾病更少。
- 未来奥利司司特的开发将基于改良释放制剂。
研究设计与样本
- 2a期前瞻性、随机、双盲、安慰剂对照试验:中重度银屑病患者随机接受30 mg口服奥利司司特速释制剂或安慰剂治疗16周。
- 1期单中心试验包含三部分:第一部分为开放标签,参与者单次接受30 mg奥利司司特改良释放和速释制剂;第二部分为开放标签,参与者在空腹、高脂餐后或低脂餐后条件下接受30 mg奥利司司特改良释放或速释制剂;第三部分为双盲,参与者接受最多60 mg奥利司司特改良释放每日两次或安慰剂治疗17天。
主要发现
- 2a期试验中,与安慰剂相比,奥利司司特速释制剂在16周时显著改善平均银屑病面积严重度指数评分。
- 1期试验显示奥利司司特改良释放与速释制剂药代动力学特性相当。
- 奥利司司特改良释放组胃肠道相关不良事件发生率为16.7%,速释组为33.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Orismilast is a high-potency phosphodiesterase 4 (PDE4) inhibitor with enhanced selectivity for the PDE4B and PDE4D subtypes. OBJECTIVES: The objective of this phase 2a trial was to examine the efficacy and safety of orismilast for psoriasis using a first-generation immediate-release (IR) formulation. The objective of the subsequent phase 1 trial was to test new formulations designed to minimize the gastrointestinal (GI)-related adverse events (AEs) observed with the first-generation IR formulation. We examined the following: (1) pharmacokinetic (PK) properties of orismilast modified release (MR) and IR, (2) food effects on PK properties of orismilast MR or IR, (3) safety of orismilast MR compared to placebo. METHODS: In a phase 2a prospective, randomized, double-blind, placebo-controlled trial, patients with moderate-to-severe psoriasis were randomized to receive 30 mg oral orismilast IR or placebo over 16 weeks. The single-site phase 1 trial consisted of three parts: (1) participants received a single 30 mg dose of orismilast MR and IR (open-label), (2) participants received 30 mg orismilast MR or IR under either fasting condition, following a high-fat meal or low-fat meal (open-label) and (3) participants received up to 60 mg orismilast MR twice-daily or a placebo for 17 days (double-blind). RESULTS: In the phase 2a trial, treatment with orismilast IR significantly improved the mean Psoriasis Area Severity Index score at week 16 compared to placebo. The phase 1 trial revealed comparable PK properties of the orismilast MR and IR formulations, with participants in the orismilast MR group experiencing fewer GI-related AEs than those receiving orismilast IR (16.7% vs. 33.3%). CONCLUSION: Orismilast IR displayed higher efficacy compared to placebo in patients with moderate-to-severe psoriasis at week 16. Orismilast MR had similar PK properties and fewer GI disorders compared to the IR formulation in healthy participants. Future development of orismilast will be based on the MR formulation.
引用
- Warren RB, Strober B, Silverberg JI, et al. Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets. J Eur Acad Dermatol Venereol. 2023. PMID: 36478476. doi:10.1111/jdv.18812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。